Business Description
Propanc Biopharma Inc
NAICS : 325412
SIC : 2834
ISIN : US74346N7012
Total Employee Number:
2Description
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.77 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 5/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History |
|---|
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 34.18 | |||||
9-Day RSI | 39.81 | |||||
14-Day RSI | 40.9 | |||||
3-1 Month Momentum % | -36.46 | |||||
6-1 Month Momentum % | -89.33 | |||||
12-1 Month Momentum % | -98.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.37 | |||||
Quick Ratio | 2.37 | |||||
Cash Ratio | 0.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -92.51 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -133.74 | |||||
ROA % | -102.48 | |||||
ROIC % | -120.06 | |||||
3-Year ROIIC % | -367.36 | |||||
ROC (Joel Greenblatt) % | -350.62 | |||||
ROCE % | -128.3 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 0.13 | |||||
Price-to-Tangible-Book | 0.13 | |||||
EV-to-EBIT | -0.26 | |||||
EV-to-EBITDA | -0.26 | |||||
EV-to-FCF | -1.08 | |||||
| Price-to-Net-Current-Asset-Value | 0.35 | |||||
Earnings Yield (Greenblatt) % | -384.62 | |||||
FCF Yield % | -122.93 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:PPCB
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Propanc Biopharma Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -16.456 | ||
| Beta | 5.1427 | ||
| 3-Year Sharpe Ratio | -0.94 | ||
| 3-Year Sortino Ratio | -1.44 | ||
| Volatility % | 213.36 | ||
| 14-Day RSI | 40.9 | ||
| 14-Day ATR ($) | 0.466572 | ||
| 20-Day SMA ($) | 1.69775 | ||
| 12-1 Month Momentum % | -98.24 | ||
| 52-Week Range ($) | 1.3 - 270.25 | ||
| Shares Outstanding (Mil) | 2.28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Propanc Biopharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Propanc Biopharma Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| First quarter earnings results for 2027 | 2026-11-30 | In 158 days | ||
| First quarter earnings results for 2026 | 2026-11-13 | In 141 days | ||
| General meeting for 2026 | 2026-10-30 | In 127 days | ||
| Annual report for 2025 | 2026-09-29 | In 96 days | ||
| 0.04:1 Stock Split | 2026-05-18 | 1.70 (-6.85%) | ||
| Third quarter earnings results for 2026 | 2026-05-14 | 2.33 (+3.33%) | ||
| Second quarter earnings results for 2025 | 2026-02-17 | 5.33 (-7.39%) | ||
| First quarter earnings results for 2025 | 2025-11-14 | 19.55 (-4.23%) | ||
| Annual report for 2024 | 2025-09-29 | 45.50 (+0.55%) | ||
| Third quarter earnings results for 2024 | 2025-05-15 | 70.00 (+0.00%) |
Show
Entries
Propanc Biopharma Inc Frequently Asked Questions
What is Propanc Biopharma Inc(PPCB)'s stock price today?
The current price of PPCB is $1.48. The 52 week high of PPCB is $270.25 and 52 week low is $1.30.
When is next earnings date of Propanc Biopharma Inc(PPCB)?
The next earnings date of Propanc Biopharma Inc(PPCB) is 2026-08-14 Est..
Does Propanc Biopharma Inc(PPCB) pay dividends? If so, how much?
Propanc Biopharma Inc(PPCB) does not pay dividend.
Guru Commentaries on NAS:PPCB
No articles.
Press Release
Articles on Propanc Biopharma Inc
No articles.
Headlines
See More- 1
Jun 11, 2026
Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings
Benzinga • 10:44am
Dow Jumps Over 250 Points; US Initial Jobless Claims Rise
Benzinga • 8:55am
Propanc Biopharma authorizes $5M share buyback program; shares surge
Seeking Alpha • 7:56am
Jun 02, 2026
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers